11.10.2016
WILEX AG DE000A11QVV0
DGAP-Adhoc: WILEX AG secures further financing with shareholder loan based on an existing financing commitment
WILEX AG / Key word(s): Financing
11.10.2016 10:34
Disclosure of an inside information according to Article 17 MAR,
transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Ad hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities
Trading Act)
- Not for distribution, publication or transmission in the USA, Canada,
Japan and Australia -
WILEX AG secures further financing with shareholder loan based on an
existing financing commitment
Munich, Germany, 11 October 2016 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
today signed a subordinated loan agreement for a total amount of up to EUR
3.7 million with its main shareholder dievini Hopp BioTech holding GmbH &
Co. KG, Walldorf, Germany (dievini). The amount of the loan corresponds to
the remaining amount of the financing commitment from November 2015 of up
to EUR 10 million that will secure the company's cash reach into the second
quarter of 2017. The other part of the commitment (EUR 6.3 million) was
invested in the company through capital increases in December 2015 and
April 2016.
The loan does not have an expiration date, is unsecured and has an interest
rate of 6% per annum. WILEX AG may access the loan when needed. The lender
is entitled to terminate the loan agreement upon certain conditions; the
loan would then become due within one month. In lieu of repayment of the
loan in cash, dievini may request repayment by way of a contribution in
kind in a capital increase.
+++ End of the ad-hoc release +++
About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany, that
serves as a parent and holding company for the Group. Research and
development focus on the operations of its subsidiary Heidelberg Pharma
GmbH in Ladenburg, which primarily advances the development of the
innovative ADC platform technology based on the compound Amanitin (ATAC
technology) and provides preclinical drug research and development
services. WILEX has diagnostic and therapeutic Phase-III drug candidates,
which are available for out-licensing to external partners. WILEX AG is
listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV /
Symbol WL6. More information is available at http://www.wilex.com/.
Contact IR/PRsupport WILEX AG MC Services AG Sylvia Wimmer Katja Arnold (CIRO) Corporate Communications Executive Director & Partner Tel.: +49 (0)89-41 31 38-29 Tel.: +49 (0)89-210 228-40 Email: investors[at]wilex.com Mobile: +49 (0)160 9360 3022 Grillparzerstr. 18, 81675 Munich Email: katja.arnold[at]mc-services.euThis communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward- looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. 11.10.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 18 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
WILEX AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6